Drug profile · INN
telisotuzumab vedotin-tllv
EMRELIS
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
telisotuzumab vedotin-tllv (EMRELIS) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-dose. Current US regulatory status: approved.
Key facts
INN telisotuzumab vedotin-tllv
Brand EMRELIS
Route SINGLE-DOSE
Formulation VIAL
Frequently asked questions
What is telisotuzumab vedotin-tllv?
telisotuzumab vedotin-tllv (EMRELIS) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-dose. Current US regulatory status: approved.
What is the brand name for telisotuzumab vedotin-tllv?
EMRELIS is a marketed brand name for telisotuzumab vedotin-tllv. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of telisotuzumab vedotin-tllv?
telisotuzumab vedotin-tllv has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.